Performance testing of the Minicare cTnI system in the Emergency Department

ISRCTN ISRCTN99484822
DOI https://doi.org/10.1186/ISRCTN99484822
Secondary identifying numbers N/A
Submission date
10/12/2014
Registration date
02/01/2015
Last edited
13/11/2017
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Heart disease is the largest single cause of death throughout the European Union. Many patients with heart attacks (myocardial infarction) come to hospital with chest pain. In order to determine if this chest pain is due to a heart attack or is due to some other cause such as a chest infection or muscular pain, tests are performed. The two most important types of tests are the electrocardiogram (ECG) and blood tests to see if there is any evidence of heart damage. The test which is now used to detect heart damage in the blood is the measurement of a molecule called cardiac cTnI. The Lab 2 Go project is a European Union funded Research and Development project involving hospitals in the European Union. The aim of this study is to determine the value of a method of measuring cardiac cTnI at the patient’s bedside (point of care testing). Point-of-care cTnI testing has the potential to accelerate diagnosis and improve patient care. A blood sample can be taken and tested by the doctor, nurse or paramedic to provide cTnI measurement during clinical assessment, rather than having to wait for laboratory results. The study aims to assess the analytical and clinical performance compared to available lab based reference systems.

Who can participate?
Adults coming to hospitals with chest pains

What does the study involve?
Blood samples tested using the point of care device under assessment

What are the possible benefits and risks of participating?
Not provided at time of registration

Where is the study run from?
Hospitals in the EU – Austria, France, Germany, Netherlands (UK)

When is the study starting and how long is it expected to run for?
December 2014 to June 2016

Who is funding the study?
European Union

Who is the main contact?
Mr Henk Peels
Henk.peels@philips.com

Study website

Contact information

Mr Henk Peels
Public

High Tech Campus
HTC29P2.69
Eindhoven
5656AE
Netherlands

Phone +31 (0)653559459
Email henk.peels@philips.com

Study information

Study designThe Lab 2 Go project is a European Union funded multicentre Research and Development project (project nr. 621035) involving 6 hospitals in the European Union. The project is a study on suspected MI patients to determine the value of a method of measuring cardiac cTnI at the patient’s bedside (point of care testing). The study aims to assess the analytical and clinical performance compared to available lab based reference systems.
Primary study designObservational
Secondary study designGather user feedback on the usability of the system in the ED
Study setting(s)Hospital
Study typeDiagnostic
Participant information sheet Available on website
Scientific titleDemonstrating Minicare, a miniaturized biophotonics platform for fast and lab-equivalent Point-of-Care diagnostics
Study acronymLab2Go
Study objectivesThe goal of the Lab2Go project is to bring a (handheld) Point-of-Care test-device to the next level of maturity by demonstrating it in real user environments.
Ethics approval(s)Proportionate Review Sub-committee of the NRES Committee South East Coast - Surrey. Ref: 14/LO/2012
Health condition(s) or problem(s) studiedMeasuring cardiac cTnI at the patient’s bedside as an aid in the diagnosis of myocardial infarction (MI)
InterventionPatient blood will be tested on the POC device and the result compared to local Troponin Lab test results. The study does not interfere with routine patient treatment and does not alter the routine diagnosis of the patients condition.
Intervention typeDevice
Pharmaceutical study type(s)
Phase
Drug / device / biological / vaccine name(s)
Primary outcome measureFor individual patients, blood samples will be tested on the POC device from up to three time points (t=0, t=2-4 hours and t = 6-24 hours). Each result is a quantitative TnI measurement which can be compared to results generated by the local Lab equipment.
Secondary outcome measuresUsers (nurses) will be observed and interviewed to gather user feedback on the use of the system.
Data regarding the hospital workflow for MI patients will be gathered to allow determining whether workflow efficiency can potentially be improved with the introduction of POC testing.
Overall study start date01/12/2014
Completion date30/06/2016

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participantsIn total for all participating hospitals 300-350 patients for analytical performance testing and 600-700 patients for clinical performance testing.
Key inclusion criteria1. ≥ 18 years old
2. Patients presenting with symptoms suggestive of ACS, at ER or CCU
3. Patients presenting for the 1st time after onset of symptoms
4. Onset of last episode of symptoms suggestive of AMI <12 hrs prior to presentation
5. Signed informed consent form
Key exclusion criteria1. Patients already admitted for the same set of symptoms at a previous healthcare institution before being transferred to the participating clinical site
2. Patients requiring emergency treatment (respiratory or cardiovascular support, arrhythmia control, coronary reperfusion)
3. Cognitive impairment or inability to understand study information
4. Unwilling or unable to provide written consent
Date of first enrolment01/12/2014
Date of final enrolment01/06/2016

Locations

Countries of recruitment

  • Austria
  • England
  • France
  • Germany
  • Netherlands
  • United Kingdom

Study participating centres

St George’s Healthcare NHS Trust
London
SW17 0QT
United Kingdom
National Institute for Health Research Sheffield, Clinical Research Facility
Sheffield
S10 2JF
United Kingdom
Stichting Catharina Ziekenhuis
Eindhoven
-
Netherlands
Klinik für Notfall- und Internistische Intensivmedizin
Nurnberg
-
Germany
Universitätsklinik für Innere Medizin III Klinisches Studienzentrum Kardiologie & Angiologie
Innsbruck
-
Austria
CHU Pitié-Salpêtrière AP-HP et Université Pierre et Marie Curie
Paris
-
France

Sponsor information

Philips Electronics Nederland, B.V. - HandHeld Diagnostics
Industry

High Tech Campus 29
Eindhoven
5656 AE
Netherlands

Phone +31(0)610212150
Email jos.rijntjes@philips.com
Website www.philips.com/minicare
ROR logo "ROR" https://ror.org/02p2bgp27

Funders

Funder type

Government

European Union funded multicentre Research and Development project (project nr. 621035)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot expected to be made available
Publication and dissemination planNo publications are envisaged related to this study.
IPD sharing planThe datasets generated during and/or analysed during the current study are not expected to be made available.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
HRA research summary 28/06/2023 No No

Editorial Notes

13/11/2017: Publication and dissemination plan updated.